NITOP®

| Each film-coated tablet contains 30 mg nimodipine, № 30

 

PHARMACOLOGIC PROPERTIES

ATC Code: C08CA06, Selective calcium channel blockers with mainly vascular effect, dihydropyridine derivatives

Nimodipine is a dihydropyridine calcium channel blocker with particular cerebrovascular effect. Nimodipine increases cerebral perfusion, particularly in poorly perfused areas, by arterial dilatation, an effect which is proportionately greater in smaller than in larger vessels.

Vasoconstrictions provoked in vitro by various vasoactive substances (e.g., serotonin, prostaglandins and histamine) or by blood and blood degradation products can be prevented or reduced by up to 75 % by nimodipine.

Nimodipine binds specifically to L-type voltage-gated calcium channels. Nimodipine has additionally been found to act as an antagonist of the mineralocorticoid receptor, or as an antimineralocorticoid.

 

THERAPEUTIC INDICATIONS

Nimodipine is indicated for:

  • Prevention of ischaemic neurological deficits following aneurysmal subarachnoid haemorrhage.
  • Treatment of functional disorders of the brain in elderly patients with severe symptoms.

© Copyright 2020 GrandMedical Group®. All rights reserved.